{"sentence_labels": [-1, 1, -1, -1], "text": "A total of 221 patients (median age, 11 years [Q1, Q3: 8, 16]; 37.6% female) were randomized (53, 56, and 56 patients to 50-\u03bcg, 100-\u03bcg, and 250-\u03bcg peanut patches, respectively, and 56 to placebo patch) across 22 study sites ( Figure 1 ). Baseline distributions of age, peanut-specific IgE or IgG4 levels, skin prick test wheal diameter, or peanut protein eliciting doses in the 4 study groups were balanced ( Table 1 ). There were 113 children (aged 6-11 years), 73 adolescents (aged 12-17 years), and 35 adults (aged 18-55 years) randomized; the median eliciting doses for children and adolescents/adults were 30 mg (Q1, Q3: 1, 100) and 100 mg (Q1, Q3: 30, 300), respectively (eFigure 2 in Supplement 2). At 12 months, overall compliance with treatment in the phase 2b trial was 97.6% (Q1, Q3: 93, 100); 6.3% of patients discontinued the study prematurely.", "section": "Study Participants", "classification_label": 0, "section_number": 16, "sentences": ["A total of 221 patients (median age, 11 years [Q1, Q3: 8, 16]; 37.6% female) were randomized (53, 56, and 56 patients to 50-\u03bcg, 100-\u03bcg, and 250-\u03bcg peanut patches, respectively, and 56 to placebo patch) across 22 study sites ( Figure 1 ).", "Baseline distributions of age, peanut-specific IgE or IgG4 levels, skin prick test wheal diameter, or peanut protein eliciting doses in the 4 study groups were balanced ( Table 1 ).", "There were 113 children (aged 6-11 years), 73 adolescents (aged 12-17 years), and 35 adults (aged 18-55 years) randomized; the median eliciting doses for children and adolescents/adults were 30 mg (Q1, Q3: 1, 100) and 100 mg (Q1, Q3: 30, 300), respectively (eFigure 2 in Supplement 2).", "At 12 months, overall compliance with treatment in the phase 2b trial was 97.6% (Q1, Q3: 93, 100); 6.3% of patients discontinued the study prematurely."], "doc_id": "34198"}